Onsdag 30 Oktober | 09:24:28 Europe / Stockholm

Svenska | English

Alvotech

Kalender

	Tid*
2024-11-13	22:30	Kvartalsrapport 2024-Q3
2024-08-16	-	Kvartalsrapport 2024-Q2
2024-05-17	-	Kvartalsrapport 2024-Q1
2023-11-14	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-06-06	-	Årsstämma
2023-05-19	-	Kvartalsrapport 2023-Q1

Beskrivning

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

Alvotech är ett bioteknikbolag som fokuserar på utveckling och tillverkning av biosimilära läkemedel. Bolagets pipeline består av biosimilar-kandidater som syftar till att behandla autoimmuna sjukdomar, ögonsjukdomar, osteoporos och cancer. Bolaget erbjuder sina produkter till patienter över hela världen. Alvotech grundades år 2013 och har sitt huvudkontor i Luxemburg.

Filter

År

Typ

Språk

Rensa

2024-10-25 14:00:00 Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 +0,28%

2024-10-25 14:00:00 Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024 +0,28%

2024-10-25 14:00:00 Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 +0,28%

2024-10-22 13:00:00 Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) +1,18%

2024-10-22 13:00:00 Alvotech veitt aukið markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn), líftæknilyfjahliðstæðu við Stelara, til meðferðar sjúkdóma í meltingarvegi +1,18%

2024-10-10 11:01:00 Evrópska lyfjastofnunin samþykkir að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva -1,14%

2024-10-10 11:01:00 European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® -1,14%

2024-10-10 11:00:00 European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® -1,14%

2024-09-25 11:01:00 Alvotech hefur klíníska rannsókn á AVT16, fyrirhugaðri líftæknilyfjahliðstæðu við Entyvio +1,66%

2024-09-25 11:01:00 Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® +1,66%

2024-09-25 11:00:00 Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® +1,66%

2024-08-26 15:15:00 Alvotech tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanley -0,91%

2024-08-26 15:15:00 Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference -0,91%

2024-08-26 15:14:00 Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference -0,91%

2024-08-15 22:15:00 Alvotech skilar mettekjum og metframlegð á öðrum ársfjórðungi og á fyrri helmingi ársins +6,29%

2024-08-15 22:15:00 Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 +6,29%

2024-08-15 10:30:00 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) +6,29%

2024-08-15 10:30:00 Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea +6,29%

2024-08-15 10:30:00 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) +6,29%

2024-08-01 22:02:00 Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET -1,20%

2024-08-01 22:01:00 Alvotech mun birta uppgjör fyrri árshelmings 2024 fimmtudaginn 15. ágúst nk. og streyma uppgjörsfundi föstudaginn 16. ágúst nk. kl. 12:00 að íslenskum tíma -1,20%

2024-08-01 22:01:00 Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET -1,20%

2024-07-22 12:35:00 STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu +0,76%

2024-07-22 12:35:00 STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe +0,76%

2024-07-22 12:30:00 STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe +0,76%

2024-07-11 10:45:00 Alvotech Announces Closing of Private Debt Financing +0,30%

2024-07-11 10:45:00 Alvotech lýkur við endurfjármögnun skulda með lægri fjármagnskostnaði og lengri lánstíma +0,30%

2024-07-11 10:45:00 Alvotech Announces Closing of Private Debt Financing +0,30%

2024-07-02 15:00:00 Alvotech kynnir jákvæða niðurstöðu virknirannsóknar á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia og Xgeva +2,39%

2024-07-02 15:00:00 Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® +2,39%

2024-07-01 23:35:00 Alvotech Issues New Shares to Holders of Convertible Bonds +2,76%

2024-07-01 23:35:00 Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf +2,76%

2024-07-01 23:35:00 Alvotech Issues New Shares to Holders of Convertible Bonds +2,76%

2024-07-01 11:10:00 Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 +2,76%

2024-07-01 11:10:00 Alvotech kynnir áætlaðar mettekjur og EBITDA framlegð á öðrum ársfjórðungi 2024 +2,76%

2024-07-01 11:10:00 Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 +2,76%

2024-06-26 10:50:00 Alvotech Receives Conversion Notices for Majority of Convertible Bonds -7,00%

2024-06-26 10:50:00 Eigendur meirihluta breytilegra skuldabréfa Alvotech nýta rétt til að breyta yfir í hlutabréf -7,00%

2024-06-26 10:50:00 Alvotech Receives Conversion Notices for Majority of Convertible Bonds -7,00%

2024-06-18 10:01:00 Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe -2,31%

2024-06-18 10:00:00 Alvotech og Advanz Pharma undirrita samning um markaðssetningu í Evrópu á fyrirhugaðri líftæknilyfjahliðstæðu við Eylea -2,31%

2024-06-18 10:00:00 Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe -2,31%

2024-06-11 10:00:00 Alvotech and STADA add to strategic alliance through denosumab partnership +2,30%

2024-06-11 10:00:00 Alvotech og STADA útvíkka samstarf sitt með nýjum samningi um AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva +2,30%

2024-06-11 10:00:00 Alvotech and STADA add to Strategic Alliance through Denosumab Partnership +2,30%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden